Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Research & Development (R&D) Day  (Replay)
    Thursday, December 06, 2018 12:00 pm EST
Toggle Summary Spring Bank Pharmaceuticals Hosts R&D Day on Pipeline of Novel Immunomodulatory Therapeutics
R&D Day to take place today, December 6, 2018, in New York City and will be webcast live HOPKINTON, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral
Toggle Summary Spring Bank Announces Additional Pre-Clinical Data on Its Second-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
HOPKINTON, Mass. , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced additional pre-clinical
Toggle Summary Spring Bank Announces Additional Inarigivir Results at AASLD Conference
*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted *New data from ACHIEVE trial demonstrates that increased baseline serum IP-10, a marker of immune activation in HBV, is a positive predictor for anti-viral
Toggle Summary Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
HOPKINTON, Mass. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will present at
Toggle Summary Spring Bank Announces Three Poster Presentations on Its Next-Generation STING Agonist Program at the AACR Special Conference on Tumor Immunology and Immunotherapy
HOPKINTON, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will present data from
Toggle Summary Spring Bank Pharmaceuticals to Host R&D Day on Thursday, December 6, 2018
HOPKINTON, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will host a Research &
Toggle Summary Spring Bank Pharmaceuticals Reports Third Quarter Financial Results
HOPKINTON, Mass. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its 2018 third quarter
Toggle Summary Spring Bank Announces Inarigivir Data Presentations at AASLD Conference
HOPKINTON, Mass. , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced it will present
Toggle Summary Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
HOPKINTON, Mass. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals, Inc. Appoints Scott Smith to its Board of Directors
Former Celgene President & COO Joins Spring Bank Board HOPKINTON, Mass. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and